Esperion Therapeutics: Still An Attractive Risk/Reward Narrative As The Earnings Clock Ticks Toward Profitability

Esperion Therapeutics stock remains a buy as strong drug franchises, growth, and global milestones outweigh risks. Learn more ...

K92 Mining Announces Strong Q3 2025 Financial Results – Record Net Cash Balance, Operating Income, EBITDA and Revenue

Record operating cash flow (before working capital adjustments) for the three months ended September 30, 2025, of $101.8 ...

Harding Loevner International Developed Markets Equity Q3 2025 Commentary

Explore our Q3 2025 analysis on why high-quality international stocks are underperforming and see our latest portfolio ...

Meta CEO Mark Zuckerberg Just Delivered Fantastic News for Nvidia Investors

During Meta's third-quarter earnings call last week, CEO Mark Zuckerberg spent quite a bit of time detailing the company's AI ...

Your Company Needs an Exit Blueprint—Even If You Never Sell It

How thinking like a buyer of your own company creates better strategic decisions—even when you never plan to sell.

Closing Bell: Nifty above 25,550, Sensex up 319 pts; IT stocks gain

Except media (down 1%), all other sectoral indices ended in the green with IT index up 1.6 percent, pharma index up nearly 1 percent, metal index up 0.6 percent. Infosys, HCL Technologies, Grasim ...